TrialBMJ open2025

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).

Michael E Weinblatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.